Trial · NCT00995007

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

NCT00995007, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2016-03-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas. Trials, record NCT00995007. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00995007

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
NCT number: NCT00995007
Status: Completed
Phases: Phase 2
Enrollment: 112 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions: ZD6474 (Vandetanib), Carboplatin
First posted: 2009-10-14
Last updated: 2016-03-29
Results first posted: 2016-03-29

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival at 6 Months	6 months	Percentage of participants who are alive and progression-free at 6 months.
Secondary	Overall Survival	Time between the first day of treatment and the day of death, up to 1.5 years	Time between the first day of treatment and the day of death.
Secondary	Number of Participants With Adverse Events	70 months and 19 days	Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival at 6 Months	6 months	The group data is displayed per the report provided to the Food and Drug Administration.	percentage of participants	NUMBER
SECONDARY	Overall Survival	Time between the first day of treatment and the day of death, up to 1.5 years	The group data is displayed per the report provided to the Food and Drug Administration.	Months	MEDIAN
SECONDARY	Number of Participants With Adverse Events	70 months and 19 days		participants	NUMBER

Source ClinicalTrials.gov

Results by group11

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Progression Free Survival at 6 Months	Glioblastoma (Combination)	1.71		percentage of participants
Progression Free Survival at 6 Months	Glioblastoma (Carboplatin Alone)	0.89		percentage of participants
Progression Free Survival at 6 Months	Anaplastic Astrocytomas (Combination)	8.7		percentage of participants
Progression Free Survival at 6 Months	Anaplastic Astrocytomas (Carboplatin Alone)	17.4		percentage of participants
Overall Survival	Glioblastoma (Combination)	5.58	95% Confidence Interval 4.60 to 8.65	Months
Overall Survival	Glioblastoma (Carboplation Alone)	5.22	95% Confidence Interval 3.78 to 7.46	Months
Overall Survival	Anaplastic Astrocytoma (Combination)	6.5	95% Confidence Interval 5.42 to 11.7	Months
Overall Survival	Anaplastic Astrocytoma (Carboplatin Alone)	9.27	95% Confidence Interval 5.52 to 43.86	Months
Number of Participants With Adverse Events	Carboplatin	55		participants
Number of Participants With Adverse Events	Vandetanib With Carboplatin	56		participants

1 to 10 of 11Source ClinicalTrials.gov

See all 11 results by group

Participant flow8

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Carboplatin	56
Overall Study	STARTED	Vandetanib With Carboplatin	56
Overall Study	Crossover to Vandetanib	Carboplatin	42
Overall Study	Crossover to Vandetanib	Vandetanib With Carboplatin	0
Overall Study	COMPLETED	Carboplatin	39
Overall Study	COMPLETED	Vandetanib With Carboplatin	54
Overall Study	NOT COMPLETED	Carboplatin	17
Overall Study	NOT COMPLETED	Vandetanib With Carboplatin	2

Source ClinicalTrials.gov

Adverse events651

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Activated partial thromboplastin time prolonged	Investigations	Carboplatin	2	56	2
other	Activated partial thromboplastin time prolonged	Investigations	Vandetanib With Carboplatin	5	56	11
other	Activated partial thromboplastin time prolonged	Investigations	Crossover to Vandetanib	1	42	1
other	Alanine aminotransferase increased	Investigations	Carboplatin	19	56	29
other	Alanine aminotransferase increased	Investigations	Vandetanib With Carboplatin	43	56	74
other	Alanine aminotransferase increased	Investigations	Crossover to Vandetanib	24	42	29
other	Alkaline phosphatase increased	Investigations	Carboplatin	4	56	4
other	Alkaline phosphatase increased	Investigations	Vandetanib With Carboplatin	17	56	20
other	Alkaline phosphatase increased	Investigations	Crossover to Vandetanib	6	42	6
other	Anemia	Blood and lymphatic system disorders	Carboplatin	30	56	67

1 to 10 of 651Source ClinicalTrials.gov

See all 651 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Carboplatin
Total, all-cause mortality	Vandetanib With Carboplatin
Total, all-cause mortality	Crossover to Vandetanib
Total, other adverse events	Carboplatin	55	56
Total, other adverse events	Vandetanib With Carboplatin	56	56
Total, other adverse events	Crossover to Vandetanib	40	42
Total, serious adverse events	Carboplatin	10	56
Total, serious adverse events	Vandetanib With Carboplatin	21	56
Total, serious adverse events	Crossover to Vandetanib	13	42

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
8931682	BACKGROUND	PubMed
12672281	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00995007

GET https://conductscience.org/api/trials/v1/NCT00995007/events?page=2

API reference For AI assistants